Athenex gets closer to clinical trials in China
Athenex Inc. (Nasdaq:ATNX) has taken another step forward in its efforts to bring an oral breast cancer drug to market in Asia.
The Buffalo-based biopharmaceutical firm received an acceptance from the Chinese Food& Drug Administration for an investigational new drug (IND) application for Oraxol, an oral version of its oral formulation of the chemotherapy formulation paclitaxel.
It’s the next in a series of okays from FDA groups across the world, including the United States, South America,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Tracey Drury Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Health Management | Investigational New Drugs | Oral Cancer | USA Health